Duration of untreated psychosis and duration of untreated illness: New Vistas

CNS Spectrums

Volumn 15, Issue 4, 2010, Pages 238-246

  Dell'Osso, Bernardo ^a   Altamura, A Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; BIPOLAR DISORDER; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; EARLY INTERVENTION; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

EID: 77952577163     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000079     Document Type: Review

References (87)

1. Malla A, Norman R, McLean T, Scholten D, Townsend L. A Canadian programme for early intervention in non-affective psychotic disorders. Aust N Z J Psychiatry. 2003;37:407-413.
2. Melle I, Larsen TK, Haahr U, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004;61:143-150.
3. Melle I, Larsen TK, Haahr U, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65:634-640.
4. Jackson D, Lawoyin R, Gaynor K, et al. Is the duration of untreated psychosis temporally stable? Eur Psychiatry. 2008;23:97-99.
5. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975-983.
6. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785-1804.
7. Clarke M, Whitty P, Browne S, et al. Suicidality in first episode psychosis. Schizophr Res. 2006;86:221-225.
8. Freidl M, Piralic Spitzl S, Aigner M. How depressive symptoms correlate with stigma perception of mental illness. Int Rev Psychiatry. 2008;20:510-514.
9. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res. 2008;42:982-990.
10. Jeppesen P, Petersen L, Thorup A, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38:1157-1166.
11. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985-991.
12. Mantere O, Suominen K, Leppämäki S, Valtonen H, Arvilommi P, Isometsä E. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipolar Disord. 2004;6:395-405.
13. Bauer M, Juckel G, Correll CU, Leopold K, Pfennig A. Diagnosis and treatment in the early illness phase of bipolar disorders. Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 5):50-54.
14. Dell'Osso B, Mundo E, Albano A, et al. Duration of untreated illness in anxiety and mood disorders. Presented at the 16th AEP Congress, Apr 5-9, 2008, Nice (F). Eur Psychiatry. 2008;23(Supp 2):S369.
15. Singh SP. Outcome measures in early psychosis; relevance of duration of untreated psychosis. Br J Psychiatry. 2007;50:s58-63.
16. Bechard-Evans L, Schmitz N, Abadi S, Joober R, King S, Malla A. Determinants of help-seeking and system related components of delay in the treatment of first-episode psychosis. Schizophr Res. 2007;96:206-214.
17. Jané-Llopis E, Hosman C, Jenkins R, Anderson P. Predictors of efficacy in depression prevention programmes. Meta-analysis. Br J Psychiatry. 2003;183:384-397.
18. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry. 2008;165:1015-1023.
19. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry. 2007;64:521-529.
20. Lawrie SM, McIntosh AM, Hall J, Owens DG, Johnstone EC. Johnstone EC. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull. 2008;34:330-340.
21. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008;34:354-366.
22. Cahn W, Rais M, Stigter FP, et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2009;19:147-151.
23. Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res. 2005;79:85-93.
24. Goldberg TE, Burdick KE, McCormack J, et al. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr Res. 2009;107:262-266.
25. Lappin JM, Morgan KD, Morgan C, et al. Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res. 2007;95:103-110.
26. Simonsen E, Friis S, Haahr U, et al. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand. 2007;116:54-61.
27. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193:203-209.
28. Altamura AC, Bassetti R, Sassella F, Salvadori D, Mundo E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res. 2001;52:29-36.
29. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res. 2003;60:47-55.
30. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996;3:241-253.
31. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
32. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol. 2007;22:249-267.
33. Häfner H, Löffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand. 1999;100:105-118.
34. Morgan C, Abdul-Al R, Lappin JM, et al. Clinical and social determinants of duration of untreated psychosis in the AESOP first-episode psychosis study. Br J Psychiatry. 2006;189:446-452.
35. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: A meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30:3719-3735.
36. Altamura AC, Dell'Osso B, Vismara S, Mundo E. May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry. 2008;23:92-96.
37. Scott J, Eccleston D, Boys R. Can we predict the persistence of depression? Br J Psychiatry. 1992;161:633-637.
38. Gormley N, O'Leary D, Costello F. First admissions for depression: is the 'no-treatment interval' a critical predictor of time to remission? J Affect Disord. 1999;54:49-54.
39. Altamura AC, Dell'Osso B, Mundo E, Dell'Osso L. Duration of untreated illness in major depressive disorder: a naturalistic study. Int J Clin Pract. 2007;61:1697-1700.
40. de Diego-Adeliño J, Portella MJ, Puigdemont D, Pérez-Egea R, Alvarez E, Pérez V. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord. 2010;120:221-225.
41. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3:115-124.
42. Suppes T, Dennehy EB, Hirschfeld RM, et al. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-886.
43. Arvilommi P, Suominen KS, Mantere OK, Leppämäki S, Valtonen H, Isometsä ET. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry. 2007;68:102-110.
44. Suominen K, Mantere O, Valtonen H, et al. Early age at onset of bipolar disorder is associated with more severe clinical features but delayed treatment seeking. Bipolar Disord. 2007;9:698-705.
45. Altamura AC, Dell'Osso B, Berlin HA, Buoli M, Bassetti R, Mundo E. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psych Clin Neurosci. In press.
46. Baethge C, Gruschka P, Smolka MN, et al. Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. J Psychiatry Neurosci. 2003;28:355-361.
47. Baethge C, Tondo L, Bratti IM, et al. Prophylaxis latency and outcome in bipolar disorders. Can J Psychiatry. 2003;48:449-457.
48. Norrholm SD, Ouimet CC. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse. 2001;42:151-163.
49. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspective from affective neuroscience. Annu Rev Psychol. 2002;53:545-574.
50. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157:115-118.
51. Videbech P, Ravnkilde B. Hippocampal volume and depression. A meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957-1966.
52. Bremner JD, Vythilingam M, Vermetten E, et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry. 2002;51:273-279.
53. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdale is due to oligodendrocytes. Biol Psychiatry. 2004;55:563-569.
54. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545-553.
55. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824-827.
56. Ongür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95:13290-13295.
57. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5:262-269.
58. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001;35:5-49.
59. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry. 1999;46:1181-1191.
60. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 2001;25:836-844.
61. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
62. Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003;28:1562-1571.
63. Lucassen PJ, Fuchs E, Czéh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry. 2004;55:789-796.
64. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034-5043.
65. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518.
66. Bienvenu OJ, Ginsburg GS. Prevention of anxiety disorders. Int Rev Psychiatry. 2007;19:647-654.
67. Roberts NP, Kitchiner NJ, Kenardy J,Bisson JI. Systematic review and meta-analysis of multiple-session early interventions following traumatic events. Am J Psychiatry. 2009;166:293-301.
68. Roberts NP, Kitchiner NJ, Kenardy J, Bisson J. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev. 2009;3:CD006869.
69. Zohar J, Sonnino R, Juven-Wetzler A, Cohen H. Can posttraumatic stress disorder be prevented? CNS Spectr. 2009;14(1 Suppl 1):44-51.
70. Wagner R, Silove D, Marnane C, Rouen D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord. 2006;20:363-371.
71. Altamura AC, Santini A, Salvadori D, Mundo E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat. 2005;1:345-347.
72. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21:864-872.
73. Altamura AC, Dell'Osso B, D'Urso N, Russo M, Fumagalli S, Mundo E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr. 2008;13:415-422.
74. Dell'Osso B, Buoli M, Hollander E, Altamura AC. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatr. 2010;11:59-65.
75. Marchall M, Rathbone J. Early intervention in Psychosis. Cochrane Database Syst Rev. 2006;4:CD004718.
76. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Early detection of psychosis - establishing a service for persons at risk. Eur Psychiatry. 2009;24:1-10.
77. Joa I, Johannessen JO, Auestad B, et al. The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull. 2008;34:466-472.
78. Merry S, McDowell H, Hetrick S, Bir J, Muller N. Psychological and/or educational interventions for the prevention of depression in children and adolescents. Cochrane Database Syst Rev. 2004;1:CD003380.
79. Cuijpers P, Van Straten A, Smit F. Preventing the incidence of new cases of mental disorders: a meta-analytic review. J Nerv Ment Dis. 2005;193:119-125.
80. Horowitz JL, Garber J. The prevention of depressive symptoms in children and adolescents: A meta-analytic review. J Consult Clin Psychol. 2006;74:401-415.
81. Sutton JM. Prevention of depression in youth: a qualitative review and future suggestions. Clin Psychol Rev. 2007;27:552-571.
82. Cuijpers P, van Straten A, Smit F, Mihalopoulos C, Beekman A. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry. 2008;165:1272-1280.
83. Gladstone TR, Beardslee WR. The prevention of depression in children and adolescents: a review. Can J Psychiatry. 2009;54:212-221.
84. Stice E, Shaw H, Bohon C, Marti CN, Rohde P. A meta-analytic review of depression prevention programs for children and adolescents: factors that predict magnitude of intervention effects. J Consult Clin Psychol. 2009;77:486-503.
85. Pratt BM, Woolfenden SR. Interventions for preventing eating disorders in children and adolescents. Cochrane Database Syst Rev. 2002;2:CD002891.
86. Griffin KW, Botvin GJ, Nichols TR, Doyle MM. Effectiveness of a universal drug abuse prevention approach for youth at high risk for substance use initiation. Prev Med. 2003;36:1-7.
87. Beekman AT, Smit F, Stek ML, Reynolds CF 3rd, Cuijpers PC. Preventing depression in high-risk groups. Curr Opin Psychiatry. 2010;23:8-11.